{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:44:57Z","timestamp":1790783097207,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T00:00:00Z","timestamp":1342483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/nrrheum.2012.106","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T14:51:23Z","timestamp":1342623083000},"page":"522-533","source":"Crossref","is-referenced-by-count":188,"title":["New insights into mechanisms of therapeutic effects of antimalarial agents in SLE"],"prefix":"10.1038","volume":"8","author":[{"given":"Daniel J.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet S.","family":"Gudsoorkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swamy R.","family":"Venuturupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,17]]},"reference":[{"issue":"Suppl. 1","key":"BFnrrheum2012106_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1177\/0961203396005001021","volume":"5","author":"DJ Wallace","year":"1996","unstructured":"Wallace, D. J. The history of antimalarials. Lupus 5 (Suppl. 1), S2\u2013S3 (1996).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR2","doi-asserted-by":"publisher","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","volume":"39","author":"C Knox","year":"2011","unstructured":"Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035\u2013D1041 (2011).","journal-title":"Nucleic Acids Res."},{"key":"BFnrrheum2012106_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/chir.530060420","volume":"6","author":"SE Tett","year":"1994","unstructured":"Tett, S. E., McLachlan, A. J., Cutler, D. J. & Day, R. O. Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6, 355\u2013359 (1994).","journal-title":"Chirality"},{"issue":"Suppl. 1","key":"BFnrrheum2012106_CR4","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/0961203396005001041","volume":"5","author":"DE Furst","year":"1996","unstructured":"Furst, D. E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5 (Suppl. 1), S11\u2013S15 (1996).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3949\/ccjm.24.2.98","volume":"24","author":"AL Scherbel","year":"1957","unstructured":"Scherbel, A. L., Schuchter, S. L. & Harrison, J. W. Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis. Cleve. Clin. Q. 24, 98\u2013104 (1957).","journal-title":"Cleve. Clin. Q."},{"key":"BFnrrheum2012106_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(05)78925-X","volume":"351","author":"JA Block","year":"1998","unstructured":"Block, J. A. Hydroxychloroquine and retinal safety. Lancet 351, 771 (1998).","journal-title":"Lancet"},{"key":"BFnrrheum2012106_CR7","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284\u20133290 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/ard.2006.067835","volume":"66","author":"N Costedoat-Chalumeau","year":"2007","unstructured":"Costedoat-Chalumeau, N. et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 66, 821\u2013824 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1191\/096120301678646092","volume":"10","author":"DJ Wallace","year":"2001","unstructured":"Wallace, D. J. Antimalarials\u2014the 'real' advance in lupus. Lupus 10, 385\u2013387 (2001).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0049-0172(10)80012-5","volume":"23","author":"RI Fox","year":"1993","unstructured":"Fox, R. I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis Rheum. 23, 82\u201391 (1993).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2012106_CR11","first-page":"375","volume":"21","author":"DJ Wallace","year":"1994","unstructured":"Wallace, D. J., Linker-Israeli, M., Hyun, S., Klinenberg, J. R. & Stecher, V. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J. Rheumatol. 21, 375\u2013376 (1994).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2012106_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","volume":"15","author":"A Wozniacka","year":"2006","unstructured":"Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P. & Sysa-Jedrzejowska, A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15, 268\u2013275 (2006).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","volume":"45","author":"CH Jang","year":"2006","unstructured":"Jang, C. H., Choi, J. H., Byun, M. S. & Jue, D. M. Chloroquine inhibits production of TNF-\u03b1, IL-1\u03b2 and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes. Rheumatology (Oxford) 45, 703\u2013710 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2012106_CR14","first-page":"1124","volume":"159","author":"A Wozniacka","year":"2008","unstructured":"Wozniacka, A. et al. The influence of antimalarial treatment on IL-1\u03b2, IL-6 and TNF-\u03b1 mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br. J. Dermatol. 159, 1124\u20131130 (2008).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2012106_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/76032","volume":"25","author":"M Napirei","year":"2000","unstructured":"Napirei, M. et al. Features of systemic lupus erythematosus in DNase1-deficient mice. Nat. Genet. 25, 177\u2013181 (2000).","journal-title":"Nat. Genet."},{"key":"BFnrrheum2012106_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00541153","volume":"1","author":"S Chitrabamrung","year":"1981","unstructured":"Chitrabamrung, S., Rubin, R. L. & Tan, E. M. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol. Int. 1, 55\u201360 (1981).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2012106_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri1957","volume":"6","author":"A Marshak-Rothstein","year":"2006","unstructured":"Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823\u2013835 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2012106_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","volume":"32","author":"AL Blasius","year":"2010","unstructured":"Blasius, A. L. & Beutler, B. Intracellular Toll-like receptors. Immunity 32, 305\u2013315 (2010).","journal-title":"Immunity"},{"key":"BFnrrheum2012106_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1365-2249.1999.00772.x","volume":"115","author":"H Vallin","year":"1999","unstructured":"Vallin, H., Blomberg, S., Alm, G. V., Cederblad, B. & Ronnblom, L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-\u03b1 (IFN-\u03b1) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115, 196\u2013202 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum2012106_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0198-8859(02)00757-7","volume":"63","author":"L Ronnblom","year":"2002","unstructured":"Ronnblom, L. & Alm, G. V. The natural interferon-\u03b1 producing cells in systemic lupus erythematosus. Hum. Immunol. 63, 1181\u20131193 (2002).","journal-title":"Hum. Immunol."},{"key":"BFnrrheum2012106_CR21","doi-asserted-by":"publisher","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","volume":"3","author":"GS Garcia-Romo","year":"2011","unstructured":"Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20. (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrrheum2012106_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/j.1460-2075.1987.tb04851.x","volume":"6","author":"AP Bird","year":"1987","unstructured":"Bird, A. P., Taggart, M. H., Nicholls, R. D. & Higgs, D. R. Non-methylated CpG-rich islands at the human \u03b1-globin locus: implications for evolution of the \u03b1-globin pseudogene. Embo J. 6, 999\u20131004 (1987).","journal-title":"Embo J."},{"key":"BFnrrheum2012106_CR23","doi-asserted-by":"publisher","first-page":"15124","DOI":"10.1074\/jbc.M313406200","volume":"279","author":"S Cornelie","year":"2004","unstructured":"Cornelie, S. et al. Direct evidence that Toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine\u2013phosphate\u2013guanine motif recognition. J. Biol. Chem. 279, 15124\u201315129 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2012106_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.intimp.2003.12.006","volume":"4","author":"Z Hong","year":"2004","unstructured":"Hong, Z. et al. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int. Immunopharmacol. 4, 223\u2013234 (2004).","journal-title":"Int. Immunopharmacol."},{"key":"BFnrrheum2012106_CR25","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4049\/jimmunol.160.3.1122","volume":"160","author":"DE Macfarlane","year":"1998","unstructured":"Macfarlane, D. E. & Manzel, L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 160, 1122\u20131131 (1998).","journal-title":"J. Immunol."},{"key":"BFnrrheum2012106_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1084\/jem.20051696","volume":"202","author":"J Vollmer","year":"2005","unstructured":"Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575\u20131585 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2012106_CR27","doi-asserted-by":"publisher","first-page":"38133","DOI":"10.1074\/jbc.M507163200","volume":"280","author":"O de Bouteiller","year":"2005","unstructured":"de Bouteiller, O. et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem. 280, 38133\u201338145 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2012106_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature07405","volume":"456","author":"SE Ewald","year":"2008","unstructured":"Ewald, S. E. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658\u2013662 (2008).","journal-title":"Nature"},{"key":"BFnrrheum2012106_CR29","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794\u20134804 (2011).","journal-title":"J. Immunol."},{"key":"BFnrrheum2012106_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/1523-1747.ep12873930","volume":"94","author":"F Furukawa","year":"1990","unstructured":"Furukawa, F., Kashihara-Sawami, M., Lyons, M. B. & Norris, D. A. Binding of antibodies to the extractable nuclear antigens SS-A\/Ro and SS-B\/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J. Invest. Dermatol. 94, 77\u201385 (1990).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum2012106_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/jid.1958.63","volume":"30","author":"B Shaffer","year":"1958","unstructured":"Shaffer, B., Cahn, M. M. & Levy, E. J. Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium. J. Invest. Dermatol. 30, 341\u2013345 (1958).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum2012106_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1191\/096120398678919912","volume":"7","author":"TQ Nguyen","year":"1998","unstructured":"Nguyen, T. Q., Capra, J. D. & Sontheimer, R. D. 4-aminoquinoline antimalarials enhance UV-B induced c-Jun transcriptional activation. Lupus 7, 148\u2013153 (1998).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/0002-9343(90)90345-E","volume":"89","author":"DJ Wallace","year":"1990","unstructured":"Wallace, D. J., Metzger, A. L., Stecher, V. J., Turnbull, B. A. & Kern, P. A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am. J. Med. 89, 322\u2013326 (1990).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2012106_CR34","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1016\/S0021-9258(19)40894-6","volume":"250","author":"JL Goldstein","year":"1975","unstructured":"Goldstein, J. L., Brunschede, G. Y. & Brown, M. S. Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339. J. Biol. Chem. 250, 7854\u20137862 (1975).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2012106_CR35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0022-2275(20)37596-9","volume":"37","author":"Y Lange","year":"1996","unstructured":"Lange, Y., Duan, H. & Mazzone, T. Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci. J. Lipid Res. 37, 534\u2013539 (1996).","journal-title":"J. Lipid Res."},{"key":"BFnrrheum2012106_CR36","doi-asserted-by":"publisher","first-page":"E593","DOI":"10.1152\/ajpendo.00159.2010","volume":"299","author":"JQ Gu","year":"2010","unstructured":"Gu, J. Q. et al. A Toll-like receptor 9-mediated pathway stimulates perilipin 3 (TIP47) expression and induces lipid accumulation in macrophages. Am. J. Physiol. Endocrinol. Metab. 299, E593\u2013E600 (2010).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrrheum2012106_CR37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1194\/jlr.R400015-JLR200","volume":"46","author":"P Tobias","year":"2005","unstructured":"Tobias, P. & Curtiss, L. K. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: Toll receptors in atherogenesis. J. Lipid Res. 46, 404\u2013411 (2005).","journal-title":"J. Lipid Res."},{"key":"BFnrrheum2012106_CR38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1365-2230.2008.03006.x","volume":"34","author":"A Lesiak","year":"2009","unstructured":"Lesiak, A. et al. Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin. Exp. Dermatol. 34, 570\u2013575 (2009).","journal-title":"Clin. Exp. Dermatol."},{"key":"BFnrrheum2012106_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0002-9440(10)63698-X","volume":"163","author":"G Pinhal-Enfield","year":"2003","unstructured":"Pinhal-Enfield, G. et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A2A receptors. Am. J. Pathol. 163, 711\u2013721 (2003).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum2012106_CR40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0037-1613033","volume":"87","author":"RG Espinola","year":"2002","unstructured":"Espinola, R. G., Pierangeli, S. S., Gharavi, A. E. & Harris, E. N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 87, 518\u2013522 (2002).","journal-title":"Thromb. Haemost."},{"key":"BFnrrheum2012106_CR41","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","volume":"115","author":"JH Rand","year":"2010","unstructured":"Rand, J. H. et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115, 2292\u20132299 (2010).","journal-title":"Blood"},{"key":"BFnrrheum2012106_CR42","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1096\/fasebj.5.8.1850705","volume":"5","author":"JF Woessner Jr.","year":"1991","unstructured":"Woessner, J. F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J. 5, 2145\u20132154 (1991).","journal-title":"Faseb J."},{"key":"BFnrrheum2012106_CR43","first-page":"472","volume":"33","author":"KM Stuhlmeier","year":"2006","unstructured":"Stuhlmeier, K. M. & Pollaschek, C. Quinacrine but not chloroquine inhibits PMA induced upregulation of matrix metalloproteinases in leukocytes: quinacrine acts at the transcriptional level through a PLA2-independent mechanism. J. Rheumatol. 33, 472\u2013480 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2012106_CR44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0961203309356455","volume":"19","author":"A Lesiak","year":"2010","unstructured":"Lesiak, A. et al. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19, 683\u2013688 (2010).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1541-7786.MCR-06-0007","volume":"4","author":"MA Merrell","year":"2006","unstructured":"Merrell, M. A. et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol. Cancer Res. 4, 437\u2013447 (2006).","journal-title":"Mol. Cancer Res."},{"key":"BFnrrheum2012106_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0300-483X(96)03319-7","volume":"110","author":"R Lullmann-Rauch","year":"1996","unstructured":"Lullmann-Rauch, R., Pods, R. & von Witzendorff, B. The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. Toxicology 110, 27\u201337 (1996).","journal-title":"Toxicology"},{"key":"BFnrrheum2012106_CR47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-3083.2006.01737.x","volume":"63","author":"E Toubi","year":"2006","unstructured":"Toubi, E. et al. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand. J. Immunol. 63, 299\u2013303 (2006).","journal-title":"Scand. J. Immunol."},{"key":"BFnrrheum2012106_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1478-811X-9-13","volume":"9","author":"R Ehsanian","year":"2011","unstructured":"Ehsanian, R., Van Waes, C. & Feller, S. M. Beyond DNA binding\u2014a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun. Signal. 9, 13 (2011).","journal-title":"Cell Commun. Signal."},{"key":"BFnrrheum2012106_CR49","doi-asserted-by":"crossref","unstructured":"[No authors listed] A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324, 150\u2013154 (1991).","DOI":"10.1056\/NEJM199101173240303"},{"key":"BFnrrheum2012106_CR50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1191\/0961203302lu203ra","volume":"11","author":"Y Molad","year":"2002","unstructured":"Molad, Y. et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11, 356\u2013361 (2002).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR51","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/art.21039","volume":"52","author":"BJ Fessler","year":"2005","unstructured":"Fessler, B. J. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52, 1473\u20131480 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR52","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168\u20131172 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR53","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza, G. et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577\u2013583 (2006).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0961203307078579","volume":"16","author":"JA James","year":"2007","unstructured":"James, J. A. et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16, 401\u2013409 (2007).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/art.27300","volume":"62","author":"SK Shinjo","year":"2010","unstructured":"Shinjo, S. K. et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62, 855\u2013862 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR56","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/acr.20097","volume":"62","author":"GJ Pons-Estel","year":"2010","unstructured":"Pons-Estel, G. J. et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res. (Hoboken) 62, 393\u2013400 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2012106_CR57","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.1780301219","volume":"30","author":"DJ Wallace","year":"1987","unstructured":"Wallace, D. J. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 30, 1435\u20131436 (1987).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR58","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/rheumatology\/kei014","volume":"44","author":"KT Ho","year":"2005","unstructured":"Ho, K. T. et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 44, 1303\u20131307 (2005).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2012106_CR59","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0961203307086503","volume":"17","author":"A Sis\u00f3","year":"2008","unstructured":"Sis\u00f3, A. et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17, 281\u2013288 (2008).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/ard.2008.093013","volume":"68","author":"R Kaiser","year":"2009","unstructured":"Kaiser, R., Cleveland, C. M. & Criswell, L. A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68, 238\u2013241 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR61","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/art.24232","volume":"61","author":"MG Tektonidou","year":"2009","unstructured":"Tektonidou, M. G., Laskari, K., Panagiotakos, D. B. & Moutsopoulos, H. M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61, 29\u201336 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR62","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.27289","volume":"62","author":"H Jung","year":"2010","unstructured":"Jung, H. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62, 863\u2013868 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR63","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/0002-9343(94)90151-1","volume":"96","author":"M Petri","year":"1994","unstructured":"Petri, M., Lakatta, C., Magder, L. & Goldman, D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96, 254\u2013259 (1994).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2012106_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00124743-199702000-00002","volume":"3","author":"A Kavanaugh","year":"1997","unstructured":"Kavanaugh, A., Adams-Huet, B., Jain, R., Denke, M. & McFarlin, J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J. Clin. Rheumatol. 3, 3\u20138 (1997).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrrheum2012106_CR65","first-page":"780","volume":"28","author":"EF Borba","year":"2001","unstructured":"Borba, E. F. & Bonfa, E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 28, 780\u2013785 (2001).","journal-title":"J. Rheumatol."},{"issue":"Suppl. 1","key":"BFnrrheum2012106_CR66","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1177\/0961203396005001051","volume":"5","author":"M Petri","year":"1996","unstructured":"Petri, M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5 (Suppl. 1), S16\u2013S22 (1996).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR67","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel, G. J. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 61, 830\u2013839 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR68","doi-asserted-by":"publisher","unstructured":"Pons-Estel, G. J. et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford) http:\/\/dx.doi.org\/10.1093\/rheumatology\/ker514 .","DOI":"10.1093\/rheumatology\/ker514"},{"key":"BFnrrheum2012106_CR69","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2764","volume":"11","author":"G Ruiz-Irastorza","year":"2009","unstructured":"Ruiz-Irastorza, G. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2012106_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20\u201328 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR71","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/acr.20002","volume":"62","author":"G Schmajuk","year":"2010","unstructured":"Schmajuk, G., Yazdany, J., Trupin, L. & Yelin, E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 386\u2013392 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2012106_CR72","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","volume":"127","author":"T Ruzicka","year":"1992","unstructured":"Ruzicka, T., Sommerburg, C., Goerz, G., Kind, P. & Mensing, H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br. J. Dermatol. 127, 513\u2013518 (1992).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2012106_CR73","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0961203308101714","volume":"18","author":"I Cavazzana","year":"2009","unstructured":"Cavazzana, I. et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 18, 735\u2013739 (2009).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR74","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","volume":"147","author":"AY Chang","year":"2011","unstructured":"Chang, A. Y. et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch. Dermatol. 147, 1261\u20131267 (2011).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum2012106_CR75","first-page":"1716","volume":"25","author":"P Rahman","year":"1998","unstructured":"Rahman, P., Gladman, D. D. & Urowitz, M. B. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J. Rheumatol. 25, 1716\u20131719 (1998).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2012106_CR76","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1067\/mjd.2000.103635","volume":"42","author":"ML Jewell","year":"2000","unstructured":"Jewell, M. L. & McCauliffe, D. P. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J. Am. Acad. Dermatol. 42, 983\u2013987 (2000).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum2012106_CR77","first-page":"244","volume":"145","author":"A Kreuter","year":"2009","unstructured":"Kreuter, A. et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch. Dermatol. 145, 244\u2013248 (2009).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum2012106_CR78","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1136\/ard.2007.072587","volume":"66","author":"G Leroux","year":"2007","unstructured":"Leroux, G. et al. Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann. Rheum. Dis. 66, 1547\u20131548 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR79","doi-asserted-by":"publisher","first-page":"L125","DOI":"10.1152\/ajplung.00539.2005","volume":"292","author":"JL Wright","year":"2007","unstructured":"Wright, J. L., Tai, H., Wang, R., Wang, X. & Churg, A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-\u03b1 signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L125\u2013L133 (2007).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"BFnrrheum2012106_CR80","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1164\/ajrccm.162.4.9910097","volume":"162","author":"S Lim","year":"2000","unstructured":"Lim, S. et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 162, 1355\u20131360 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrrheum2012106_CR81","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0002-9149(02)02284-1","volume":"89","author":"EA Bermudez","year":"2002","unstructured":"Bermudez, E. A., Rifai, N., Buring, J. E., Manson, J. E. & Ridker, P. M. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol. 89, 1117\u20131119 (2002).","journal-title":"Am. J. Cardiol."},{"key":"BFnrrheum2012106_CR82","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0248-8663(04)00266-8","volume":"25","author":"D Lardet","year":"2004","unstructured":"Lardet, D. et al. Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study [French]. Rev. Med. Interne 25, 786\u2013791 (2004).","journal-title":"Rev. Med. Interne"},{"key":"BFnrrheum2012106_CR83","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/jid.2011.167","volume":"131","author":"S Wahie","year":"2011","unstructured":"Wahie, S. et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J. Invest. Dermatol. 131, 1981\u20131986 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum2012106_CR84","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3899\/jrheum.090403","volume":"36","author":"I Turchin","year":"2009","unstructured":"Turchin, I., Bernatsky, S., Clarke, A. E., St-Pierre, Y. & Pineau, C. A. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J. Rheumatol. 36, 2691\u20132693 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2012106_CR85","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archdermatol.2008.594","volume":"145","author":"S Moghadam-Kia","year":"2009","unstructured":"Moghadam-Kia, S. et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch. Dermatol. 145, 255\u2013260 (2009).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum2012106_CR86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/archdermatol.2011.342","volume":"148","author":"EW Piette","year":"2012","unstructured":"Piette, E. W. et al. Impact of smoking in cutaneous lupus erythematosus. Arch. Dermatol. 148, 317\u2013322 (2012).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum2012106_CR87","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/0002-9343(88)90359-2","volume":"85","author":"A Parke","year":"1988","unstructured":"Parke, A. Antimalarial drugs and pregnancy. Am. J. Med. 85, 30\u201333 (1988).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2012106_CR88","first-page":"1715","volume":"23","author":"A Parke","year":"1996","unstructured":"Parke, A. & West, B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J. Rheumatol. 23, 1715\u20131718 (1996).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2012106_CR89","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/ard.55.7.486","volume":"55","author":"NM Buchanan","year":"1996","unstructured":"Buchanan, N. M. et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann. Rheum. Dis. 55, 486\u2013488 (1996).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR90","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"ME Clowse","year":"2006","unstructured":"Clowse, M. E., Magder, L., Witter, F. & Petri, M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640\u20133647 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR91","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2009.119263","volume":"69","author":"PM Izmirly","year":"2010","unstructured":"Izmirly, P. M. et al. Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69, 1827\u20131830 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2012106_CR92","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1191\/096120301678646137","volume":"10","author":"RA Levy","year":"2001","unstructured":"Levy, R. A. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10, 401\u2013404 (2001).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR93","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.autrev.2004.11.009","volume":"4","author":"N Costedoat-Chalumeau","year":"2005","unstructured":"Costedoat-Chalumeau, N., Amoura, Z., Huong, D. L., Lechat, P. & Piette, J. C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4, 111\u2013115 (2005).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum2012106_CR94","first-page":"1152","volume-title":"Dubois Lupus Erythematosus","author":"DJ Wallace","year":"2007","unstructured":"Wallace, D. J. in Dubois Lupus Erythematosus 7th edn (eds Wallace, D. J. & Hahn, B. H.) 1152\u20131176 (Lippincott Williams & Wilkins, Philadelphia, 2007)."},{"key":"BFnrrheum2012106_CR95","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0733-8635(05)70236-9","volume":"19","author":"MJ Van Beek","year":"2001","unstructured":"Van Beek, M. J. & Piette, W. W. Antimalarials. Dermatol. Clin. 19, 147\u2013160, ix (2001).","journal-title":"Dermatol. Clin."},{"key":"BFnrrheum2012106_CR96","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","volume":"118","author":"MF Marmor","year":"2011","unstructured":"Marmor, M. F., Kellner, U., Lai, T. Y., Lyons, J. S. & Mieler, W. F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118, 415\u2013422 (2011).","journal-title":"Ophthalmology"},{"key":"BFnrrheum2012106_CR97","unstructured":"Venuturupalli, S. R., Gudsoorkar, V. S. & Wallace, D. J. Revisiting antimalarials in systemic lupus erythematosus: developments of translational clinical interest. J. Rheumatol. (in press)."},{"key":"BFnrrheum2012106_CR98","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1741-7015-8-77","volume":"8","author":"DJ Wallace","year":"2010","unstructured":"Wallace, D. J. Advances in drug therapy for systemic lupus erythematosus. BMC Med. 8, 77 (2010).","journal-title":"BMC Med."},{"key":"BFnrrheum2012106_CR99","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1191\/0961203302lu147rr","volume":"11","author":"A Wozniacka","year":"2002","unstructured":"Wozniacka, A., Carter, A. & McCauliffe, D. P. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 11, 71\u201381 (2002).","journal-title":"Lupus"},{"key":"BFnrrheum2012106_CR100","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/ar1897","volume":"8","author":"P Lopez","year":"2006","unstructured":"Lopez, P., Gomez, J., Mozo, L., Gutierrez, C. & Suarez, A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res. Ther. 8, R42 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2012106_CR101","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","volume":"8","author":"J Collinge","year":"2009","unstructured":"Collinge, J. et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 8, 334\u2013344 (2009).","journal-title":"Lancet Neurol."},{"key":"BFnrrheum2012106_CR102","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2217\/fon.09.127","volume":"5","author":"K Gurova","year":"2009","unstructured":"Gurova, K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol. 5, 1685\u20131704 (2009).","journal-title":"Future Oncol."},{"key":"BFnrrheum2012106_CR103","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.2042-7158.1982.tb06211.x","volume":"34","author":"SA Adelusi","year":"1982","unstructured":"Adelusi, S. A. & Salako, L. A. Tissue and blood concentrations of chloroquine following chronic administration in the rat. J. Pharm. Pharmacol. 34, 733\u2013735 (1982).","journal-title":"J. Pharm. Pharmacol."},{"key":"BFnrrheum2012106_CR104","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.21571","volume":"54","author":"L Ronnblom","year":"2006","unstructured":"Ronnblom, L., Eloranta, M. L. & Alm, G. V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54, 408\u2013420 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2012106_CR105","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1182\/blood.V87.11.4731.bloodjournal87114731","volume":"87","author":"MJ Aman","year":"1996","unstructured":"Aman, M. J. et al. Interferon-\u03b1 stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 87, 4731\u20134736 (1996).","journal-title":"Blood"},{"key":"BFnrrheum2012106_CR106","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.smim.2011.01.009","volume":"23","author":"L Ronnblom","year":"2011","unstructured":"Ronnblom, L., Alm, G. V. & Eloranta, M. L. The type I interferon system in the development of lupus. Semin. Immunol. 23, 113\u2013121 (2011).","journal-title":"Semin. Immunol."},{"key":"BFnrrheum2012106_CR107","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4049\/jimmunol.1100450","volume":"187","author":"E Villanueva","year":"2011","unstructured":"Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538\u2013552 (2011).","journal-title":"J. Immunol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T06:11:49Z","timestamp":1714198309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2012.106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,17]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFnrrheum2012106"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2012.106","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,17]]}}}